Genmab

Genmab Completes Acquisition of ProfoundBio

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) and ADC technologies for the treatment of cancers.

Genmab to Acquire ProfoundBio for $1.8 Billion

Danish drugmaker Genmab has agreed to buy privately-owned US biotechnology company ProfoundBio for $1.8 billion. ProfoundBio develops novel ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors.

AbbVie Agrees Cancer Collaborations

J&J Steps Up Partnership Drive with Four New Centres

Genmab CEO Worried By Takeover Risk

Top-Feature

Predictive Simulation in Pharma Production

When Every Temperature Change Determines the Process

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

AbbVie Inc.